TITLE

Full Disclosure: Toward a Participatory and Risk-Limiting Approach to Neuroleptic Drugs

AUTHOR(S)
Aderhold, Volkmar; Stastny, Peter
PUB. DATE
March 2007
SOURCE
Ethical Human Psychology & Psychiatry;Spring2007, Vol. 9 Issue 1, p35
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Following the many clinical studies of neuroleptic treatment and the resulting practice guidelines and algorithms that have been established by various psychiatric associations, there seems to be little room for considering other treatment concepts that may be at variance with these guidelines: the earlier and the more sustainedly that neuroleptics are taken, the better--this is currently the widely accepted basic principle. If this were indeed correct, service users would have only negligible input into their treatment with neuroleptics. For therapists, there would be little more to do than to inform patients fully about these medications and their untoward effects. The elbow room could be substantially increased if clinical experiences and scientific results that are frequently ignored were to be considered. Such information will be presented in this article, with the aim of enhancing the agency and creativity of users and mental health professionals and of advocating for patient-centered and context-oriented advances in psychiatry. Critical assessments of neuroleptic treatment will be followed by a presentation of the therapeutic potential of complex psychosocial interventions, which enable the avoidance of neuroleptic medications in 40%-70% of instances; and finally, the principles of an approach that we would call participatory neuroleptic treatment will be outlined.
ACCESSION #
25121062

 

Related Articles

  • Comprehensive family therapy: an effective approach for cognitive rehabilitation in schizophrenia. Jun Cai; Yi Zhu; Weibo Zhang; Yanfeng Wang; Chen Zhang // Neuropsychiatric Disease & Treatment;2015, Vol. 11, p1247 

    Background: Antipsychotic medication has limited abilities to improve the cognitive impairments that accompany schizophrenia. Adding psychosocial treatment may result in marked improvements in cognitive function, as compared to antipsychotic treatment alone. We hypothesized that a combination of...

  • Strategies for increasing treatment compliance: The role of long-acting antipsychotics. Love, Raymond C. // American Journal of Health-System Pharmacy;11/15/2002 Supplement, Vol. 59, pS10 

    Increased patient compliance with antipsychotic medications is associated with increased efficacy and reduced rates of rehospitalization. It can improve treatment outcomes for patients and reduce costs for society. An understanding of the reasons for noncompliance is essential in formulating...

  • Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. Csernansky, J.G.; Schuchart, E.K.; Csernansky, John G; Schuchart, Emily K // CNS Drugs;2002, Vol. 16 Issue 7, p473 

    Recent studies suggest that the risk of relapse in patients with schizophrenia is approximately 3.5% per month. Predictors of more frequent relapses include poor compliance with antipsychotic drug treatment, severe residual psychopathology, poor insight into the illness and the need for...

  • CRIANZA Y ESQUIZOFRENIA. Benitez Camacho, Erika; Chévez Leén, Enrique; Ontiveros Uribe, Martha P. // Salud Mental;abr2005, Vol. 28 Issue 2, p59 

    Introduction. Schizophrenia is a chronic psychotic disorder whose prevalence in adults is from 0.5 to 1.5%, and its annual incidence ranks from 0.5 to 5 by each 10,000 inhabitants. Antipsychotic medications have shown to be effective in the treatment of acute psychosis and the prevention of...

  • Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks. Lysaker, Paul H. // Evidence Based Mental Health;Aug2006, Vol. 9 Issue 3, p71 

    The article comments on the study by R.S.E. Keefe and colleagues on the effectiveness of olanzapine and risperidone in treating neurocognitive disorders than haloperidol in people with schizophrenia. The results of the study failed to suggest any differences in the overall neurocognitive...

  • Compliance with treatment and its relevance for the management of schizophrenia. Hofer, Alex; Fleischhacker, W. Wolfgang // Hot Topics in Neurology & Psychiatry;Jun2011, Issue 11, p7 

    Poor compliance with treatments for schizophrenia limits their effectiveness and results in an increased risk of relapse, a greater likelihood of hospital admission, a longer duration of hospitalization, as well as antipsychotic treatment resistance and development of chronic psychosis. Although...

  • Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia. Parellada, Eduard; Velligan, Dawn I.; Emsley, Robin; Kissling, Werner // Schizophrenia Research & Treatment;2012, p1 

    Long-acting injectable antipsychotics (LAIAs) may improve adherence to treatment and reduce the rate of relapse and rehospitalization in first-episode or recent-onset schizophrenia (e.g., less than 2?years of illness duration). However, despite their potential advantages, LAIAs are underutilised...

  • Sexual dysfunction in outpatients with schizophrenia in Turkey: a cross-sectional study. HOCAOGLU, Cicek; CELIK, Fatmagul H.; KANDEMIR, Gokhan; GUVELI, Hulya; BAHCECI, Bulent // Shanghai Archives of Psychiatry;Dec2014, Vol. 26 Issue 6, p347 

    Background: Sexual dysfunction is one of several factors related to medication compliance in patients taking antipsychotic medication but the magnitude of this problem is unknown. Aim: Compare the self-reported sexual functioning of clinically stable patients with schizophrenia taking...

  • Does compliance therapy improve use of antipsychotic medication? Ilott, Rebecca // British Journal of Community Nursing;Nov2005, Vol. 10 Issue 11, p514 

    Non-compliance with prescribed antipsychotic medication is common among people diagnosed with schizophrenia and is associated with high relapse rates. Compliance therapy is an intervention to promote compliance, developed from motivational interviewing and cognitive behavioural therapy. This...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics